Alex Soriano, MD
Obstetrics & Gynecology · Philadelphia, PANPI 1457779472
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Astellas Pharma US Inc at 55.7% of the total. Reporting peaked in 2023 at $11,126 and has fallen 78.3% since, to $2,416 in 2025. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $103.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$12K
- Medtronic$4K
- Coloplast$1K
- Boston Scientific$1K
- AbbVie$853
- Caldera Medical, Inc$286
- plus $2K from 32 others
Across 1 payment — averaging $976.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$976
What the payments were for
- Speaking & faculty fees$12,74558%
- Travel & lodging$2,0779%
- Food & beverage$7,03732%
- Education$1321%
- Gifts$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $12,303 |
| Medtronic(2 entities) | 67 | $4,386 |
| Coloplast | 23 | $1,381 |
| Boston Scientific | 15 | $1,196 |
| AbbVie(2 entities) | 26 | $853 |
| Caldera Medical, Inc | 3 | $286 |
| Axonics, Inc. | 3 | $182 |
| Sumitomo Pharma America, Inc. | 7 | $160 |
| Conmed Corporation | 1 | $149 |
| 180 Medical, Inc. | 4 | $106 |
| Olympus America Inc. | 5 | $99 |
| Urovant Sciences Inc | 4 | $90 |
| Bayer | 3 | $87 |
| Bluewind Medical | 3 | $79 |
| Teleflex LLC | 4 | $73 |
| Mission Pharmacal Company | 4 | $67 |
| Merck | 4 | $66 |
| Coopersurgical, Inc. | 1 | $55 |
| Smith+Nephew | 2 | $39 |
| Myovant Sciences Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Baxter Healthcare | 1 | $30 |
| Hollister Incorporated | 1 | $28 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Blue Earth Diagnostics | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Photocure Inc | 1 | $22 |
| Trevena, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Telix Pharmaceuticals | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,073 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 202 | $170,154 |
| MyrbetriqMirabegron | 189 | $143,586 |
| Estradiol | 285 | $16,566 |
| Methenamine Hippurate | 200 | $11,441 |
| Trospium Chloride ErTrospium Chloride | 34 | $5,712 |
| Darifenacin ErDarifenacin Hydrobromide | 18 | $3,886 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 201 | $2,125 |
| Solifenacin Succinate | 49 | $2,002 |
| Trimethoprim | 21 | $1,568 |
| Ibuprofen | 151 | $1,043 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $668 |
| Clobetasol Propionate | 14 | $485 |
| Cephalexin | 29 | $250 |
| Amitriptyline Hcl | 20 | $145 |
| Oxycodone Hcl | 68 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $160 | $170,154202 claims |
| Astellas Pharma US IncMyrbetriq | $12,303 | $143,586189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Philadelphia
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Jamille Nagtalon-RamosPhiladelphia$183K
- Matthew BesharaPhiladelphia$56K
- Karolynn EcholsPhiladelphia$38K
- Miriam RaffeldPhiladelphia$33K
- Dana ShanisPhiladelphia$33K
- Dacarla AlbrightPhiladelphia$20K
- Rupsa BoeligPhiladelphia$19K
- Aletha AkersPhiladelphia$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.